Concepedia

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer

Jun Liang, Robert A. Blake, Jae H. Chang, Stephen Daly, Antonio G. DiPasquale, Lori S. Friedman, Thomas Gelzleichter, Matthew Gill, Jennifer M. Giltnane, Simon Goodacre,

Journal of Medicinal Chemistry · 2021 · 135 citations · 36 references

DOIFull text

Open access

Concepts

Abstract

is being evaluated in Phase III clinical trials.

References

36

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2021 · 112.5K citations · Full text

, , +16

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.9K citations

, , +17

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

Jennet Harvey, Gary M. Clark, C. Kent Osborne et al. · Journal of Clinical Oncology · 1999 · 2.1K citations

, , +17

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

, , +17

Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *

B. Fisher, Joseph P. Costantino, Carol Redmond et al. · JNCI Journal of the National Cancer Institute · 1994 · 1.3K citations

, , +14